WGS

Business Context and Reporting Period

This Form 8-K Current Report was filed by GeneDx Holdings Corp. on January 2, 2025. The filing discloses the appointment of a new Chief Operating Officer and details the associated compensatory arrangements.

Key Financial Metrics

This filing does not report revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on executive compensation terms.

• Base Salary: $450,000 annually.
• Target Annual Bonus: 50% of base salary ($225,000).
• Sign-on Bonuses: Two payments of $75,000 each, contingent on employment through July 2, 2025, and July 2, 2026.
• Equity Grant: Restricted Stock Units (RSUs) with an aggregate grant-date value of $2,700,000, vesting over four years.

Material Changes

The primary material change is the addition of Bryan Dechairo, Ph.D., as Chief Operating Officer, effective January 2, 2025. Dr. Dechairo will oversee Product & Technology, Operations, Medical Affairs, Innovation, and Program Management, reporting directly to CEO Katherine Stueland.

Outlook, Risks, and Contingencies

Employment Terms: The agreement has an initial three-year term with automatic one-year renewals. Severance Provisions:

• Standard Termination: If terminated without "cause" or resigns for "good reason," Dr. Dechairo receives 9 months of base salary and 12 months of health coverage.
• Change in Control: If termination occurs within 12 months of a change in control, benefits increase to 12 months of base salary, a lump sum equal to one times the target annual bonus, 12 months of health coverage, and accelerated vesting of equity awards.

Risks: The filing notes that the description of the employment agreement is qualified by the full text of the agreement attached as Exhibit 10.1.

Investor Verification Checklist

• Verify the full text of the Employment Agreement (Exhibit 10.1) for specific definitions of "cause" and "good reason."
• Confirm the vesting schedule and performance conditions for the $2.7 million RSU grant.
• Review the press release (Exhibit 99.1) for additional strategic context regarding the new COO's role.
• Monitor future filings for the impact of the new executive leadership on operational strategy.